GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Ensysce Biosciences ENSC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.36

+9.98%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$5.1m

FY2017FY2025

Net income

−$10.2m

FY2017FY2025

Free cash flow

−$7.9m

FY2017FY2025

Shareholders' equity

$3.2m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$5.1m$5.2m$2.2m$2.5m$3.5m$3.9m$1.8m——
Gross profit−$5.3m−$2.0m−$5.4m−$17.3m$3.5m$3.9m−$3.3m−$1.6m—
Research and development$10.4m$7.2m$7.6m$19.8m$4.7m$4.4m$3.4m——
Operating income−$10.2m−$6.7m−$10.7m−$24.2m−$19.9m−$1.6m−$3.3m−$959,240−$147,000
Net income−$10.2m−$8.0m−$10.6m−$25.0m−$29.1m$56,770$1.5m$2.1m−$31,193
Diluted earnings per share-0.40-6.50-4.69-82.33-290.300.010.240.35-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$7.5m$5.6m$2.7m$5.9m$16.4m$351,807$196.5m$204.8m$202.4m
Cash and short-term investments$4.3m$3.5m$1.1m$3.1m$12.3m$194,214$1.1m$1.7m$2.1m
Total liabilities$4.6m$2.2m$3.4m$9.9m$24.6m$7.0m$10.3m$7.4m$7.2m
Debt$306,708$301,660$854,697$4.4m$17.2m$5.1m$3.2m——
Shareholders' equity$3.2m$3.7m−$322,858−$4.0m−$8.2m−$6.7m$186.2m$197.4m$195.3m
Shares outstanding26m1m2m0m0m6m6m6m6m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$7.8m−$7.5m−$10.8m−$17.9m−$8.2m−$1.2m$11.0m−$1.2m−$251,831
Capital spending−$123,643—−$2———−$4——
Free cash flow−$7.9m−$7.5m−$10.8m−$17.9m−$8.2m−$1.2m$11.0m−$1.2m−$251,831
Dividends paid—−$290.0m−$12,937−$913,204−$803.14bn—−$500,000——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.2m$960,999$1.9m$493,104$1.4m$1.3m$1.3m$3.4m
Gross profit$1.2m$954,466—−$2.5m−$551,992$1.3m−$2.5m$1.7m
Operating income−$2.6m−$3.6m−$2.8m−$3.7m−$1.8m−$2.0m−$3.6m$644,746
Net income−$2.6m−$3.6m−$2.8m−$3.7m−$1.7m−$1.9m−$3.6m$661,769
Diluted earnings per share-0.20-0.27-0.11-0.15-0.07-0.08-2.900.54
Cash from operations−$1.0m−$3.0m−$1.0m−$1.0m−$2.0m−$1.0m—−$1.0m
Total assets$3.0m$2.2m$7.5m$3.2m$5.6m$4.6m$5.6m$9.4m
Cash and short-term investments$676,704$745,482$4.3m$1.7m$2.2m$3.1m$3.5m$4.2m
Debt$196,842$245,849$306,708$387,702$424,521$257,383$301,660$387,176
Shareholders' equity−$781,697−$340,042$3.2m$1.2m$3.4m$3.0m$3.7m$6.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue26.2%5.2%—
Operating income-24.9%44.7%—
Net income-25.9%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-71.2%-199.5%-100.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-2.3-1.3-3.4-1.6-27.2
Price to sales4.61.916.116.2224.4

Share price return

Finished calendar years

20252024202320222021202020192018
Return-81%-64%-90%-97%-74%9%5%3%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 15-to-1 reverse split · 6 Dec 2024
  • 12-to-1 reverse split · 31 Mar 2023
  • 20-to-1 reverse split · 28 Oct 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.